Filing Details

Accession Number:
0001209191-19-046913
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-08-20 20:27:57
Reporting Period:
2019-08-16
Accepted Time:
2019-08-20 20:27:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1337553 Aerie Pharmaceuticals Inc AERI Biological Products, (No Disgnostic Substances) (2836) 203109565
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1581754 B. James Tananbaum 600 Montgomery Street
Suite 4500
San Francisco CA 94111
No No Yes No
1594912 Foresite Capital Management Ii, Llc 600 Montgomery Street
Suite 4500
San Francisco CA 94111
No No Yes No
1594914 Foresite Capital Fund Ii, L.p. 600 Montgomery Street
Suite 4500
San Francisco CA 94111
No No Yes No
1645157 Foresite Capital Management Iii, Llc 600 Montgomery Street
Suite 4500
San Francisco CA 94111
No No Yes No
1645158 Foresite Capital Fund Iii, L.p. 600 Montgomery Streeet
Suite 4500
San Francisco CA 94111
No No Yes No
1704131 Foresite Capital Fund Iv, L.p. 600 Montgomery Street
Suite 4500
San Francisco CA 94111
No No Yes No
1704132 Foresite Capital Management Iv, Llc 600 Montgomery Street
Suite 4500
San Francisco CA 94111
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-08-16 100,000 $24.23 2,150,477 No 4 P Indirect See Footnote
Common Stock Acquisiton 2019-08-19 3,847 $23.34 2,154,324 No 4 P Indirect See Footnote
Common Stock Acquisiton 2019-08-20 50,000 $23.21 2,204,324 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Footnotes
  1. This transaction was executed in multiple trades at prices ranging from $23.73 to $24.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
  3. This transaction was executed in multiple trades at prices ranging from $23.22 to $23.42. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. This transaction was executed in multiple trades at prices ranging from $22.82 to $23.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.